💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rosiglitazone

CHEMBL121 Phase 4 Approved Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
357.4 g/mol
LogP
3.1
Phase
4

A thiazolidinedione insulin sensitizer used to treat type 2 diabetes by making the body's cells more responsive to insulin, reducing blood glucose levels. Its use has become restricted in many countries due to concerns about increased cardiovascular risk, particularly heart failure.

Molecular Weight

357.4000 g/mol

LogP

3.10

TPSA

96.80 Ų

Lipinski RO5

Pass

Therapeutic Areas

Alzheimer's Disease Asthma Bipolar Disorder Bladder Cancer Breast Cancer Cardiovascular Disease Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Endometriosis Gastroesophageal Reflux Disease Heart Failure Hepatitis C HIV/AIDS Hyperlipidemia Hypertension Infectious Disease Inflammatory Bowel Disease Lymphoma Malaria Melanoma Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Obesity Parkinson's Disease Prostate Cancer Respiratory Disease Schizophrenia Stroke Thyroid Cancer Type 2 Diabetes

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1

                

                

                
                

                    
InChI

                    
InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H19N3O3S

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
Rotatable Bonds

                        
7

                    

                    
                    
                    

                        
Heavy Atoms

                        
25

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
A thiazolidinedione insulin sensitizer used to treat type 2 diabetes by making the body's cells more responsive to insulin, reducing blood glucose levels. Its use has become restricted in many countries due to concerns about increased cardiovascular risk, particularly heart failure.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Rosiglitazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL121.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 77999.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.